Founded in **2008**, Bioveritas began with a core focus on high-quality laboratory services. Over the past nearly two decades, we have continuously evolved, transitioning from traditional service provision to becoming a leader in **Next-Generation Diagnostics (NGD)** and **Multi-Site Data Integration**.
Our vision is to eliminate the bottlenecks in medical research and diagnostic development—namely, data fragmentation and assay variability. We bridge the gap between initial scientific discovery and scalable clinical application, ensuring every diagnostic is robust, reproducible, and regulatory-ready.
We believe that the future of health equity lies in scalable, high-sensitivity diagnostic tools supported by impeccable data standards.
Specializing in assays that deliver both **high sensitivity and high throughput**. We implement digital PCR, advanced sequencing, and automation to detect low-abundance targets and process samples at massive scale.
Building secure, interoperable data frameworks for multi-site studies (UK and global). We ensure compliance with **UK GDPR, MHRA, and ISO standards**, turning fragmented data into unified, traceable research assets.
From initial concept to regulatory submission, we design, validate, and scale bespoke molecular and immunological assays. Our focus is on achieving consistency and eliminating cross-site variability in experimental data.
While our operational standards are global, our approach is deeply contextual. We partner with universities, NHS research centres (in the UK), and biotech firms worldwide. Our infrastructure is designed to plug directly into complex research networks, fostering secure data sharing and accelerating clinical translation in diverse populations.
**Our commitment is simple:** Deliver validated, actionable science that reduces time-to-discovery and ultimately improves patient outcomes globally.